Sai Life Sciences Intrinsic Value
SAILIFE • Healthcare
Current Stock Price
₹959.95
Primary Intrinsic Value
₹352.88
Market Cap
₹2016 Cr
+100.0%
Upside
Median Value
₹1919.90
Value Range
₹288 - ₹2031
Assessment
Trading Below Calculated Value
Safety Margin
50.0%
SAILIFE Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹352.88 | ₹282.30 - ₹423.46 | -63.2% | EPS: ₹16.04, Sector P/E: 22x |
| Book Value Method | asset | ₹2026.67 | ₹1824.00 - ₹2229.34 | +111.1% | Book Value/Share: ₹1013.33, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1919.90 | ₹1727.91 - ₹2111.89 | +100.0% | Revenue/Share: ₹1053.33, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1919.90 | ₹1727.91 - ₹2111.89 | +100.0% | EBITDA: ₹644.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹2031.03 | ₹1624.82 - ₹2437.24 | +111.6% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹287.99 | ₹259.19 - ₹316.79 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹287.99 | ₹259.19 - ₹316.79 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹1919.90 | ₹1727.91 - ₹2111.89 | +100.0% | ROE: 15.8%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹604.74 | ₹544.27 - ₹665.21 | -37.0% | EPS: ₹16.04, BVPS: ₹1013.33 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
SAILIFE Intrinsic Value Analysis
What is the intrinsic value of SAILIFE?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Sai Life Sciences (SAILIFE) is ₹1919.90 (median value). With the current market price of ₹959.95, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹287.99 to ₹2031.03, indicating ₹287.99 - ₹2031.03.
Is SAILIFE undervalued or overvalued?
Based on our multi-method analysis, Sai Life Sciences (SAILIFE) appears to be trading below calculated value by approximately 100.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 5.03 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 15.8% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 27.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.70x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Sai Life Sciences
Additional stock information and data for SAILIFE
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹314 Cr | ₹46 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹263 Cr | ₹168 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹219 Cr | ₹170 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹105 Cr | ₹54 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹-36 Cr | ₹-166 Cr | Negative Cash Flow | 3/10 |